C4 Therapeutics, Inc.
CCCC
$4.24
$0.163.92%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 7.95% | -44.15% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 7.95% | -44.15% | |||
| Cost of Revenue | -0.55% | 135.01% | |||
| Gross Profit | 3.38% | -122.70% | |||
| SG&A Expenses | -7.91% | 1.66% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.57% | -0.66% | |||
| Operating Income | 4.90% | -20.05% | |||
| Income Before Tax | 5.95% | -23.39% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 5.95% | -22.66% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 5.95% | -22.66% | |||
| EBIT | 4.90% | -20.05% | |||
| EBITDA | 4.57% | -20.53% | |||
| EPS Basic | 9.28% | -13.63% | |||
| Normalized Basic EPS | 13.08% | -14.44% | |||
| EPS Diluted | 9.28% | -13.63% | |||
| Normalized Diluted EPS | 13.08% | -14.44% | |||
| Average Basic Shares Outstanding | 3.67% | 7.96% | |||
| Average Diluted Shares Outstanding | 3.67% | 7.96% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||